Search research articles
Contact Us
Filters
Showing results (181-190 of 336) with videos related to
Page
of 34
Sort By:
Critical Reviews in Oncology/Hematology
|
February 9, 2025
Unraveling the link between cholesterol and immune system in cancer: From biological mechanistic insights to clinical evidence. A narrative review
Federica Pecci, Valeria Cognigni, Giulia Claire Giudice, et al.
Immunotherapy
|
August 6, 2024
A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study
Shobana Anpalakhan, Giuseppe Luigi Banna, Sara Elena Rebuzzi, et al.
Future Oncology (London, England)
|
March 12, 2015
Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients
Orazio Caffo, Giovanni Lo Re, Teodoro Sava, et al.
Therapeutic Advances in Medical Oncology
|
March 3, 2022
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
Sara Elena Rebuzzi, Luigi Cerbone, Alessio Signori, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
July 11, 2024
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors
Giulia Mazzaschi, Fabiana Perrone, Giuseppe Maglietta, et al.
Journal of Kidney Cancer and VHL
|
October 20, 2025
Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI Study
Giulia Airò, Annalisa Guida, Alessio Gili, et al.
BJU International
|
February 28, 2012
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey
Cristina Masini, Roberto Sabbatini, Camillo Porta, et al.
Journal for Immunotherapy of Cancer
|
January 6, 2026
Dissecting the impact of Controlling Nutritional Status (CONUT) score on survival outcomes and immune-inflammatory profiles in patients with advanced NSCLC undergoing first-line immunotherapy
Federica Pecci, Giulia Mazzaschi, Alessandra Dodi, et al.
Critical Reviews in Oncology/Hematology
|
May 8, 2023
A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitoRS in solid tumors: The OTHERS study
Giorgio Bogani, Michela Cinquini, Diego Signorelli, et al.
Clinical Genitourinary Cancer
|
August 23, 2024
Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the Kidney
Giulia Claire Giudice, Marco Maruzzo, Elena Verzoni, et al.
Page
of 34
Search research articles
Search
Showing results (181-190 of 336) with videos related to
Sort By:
Page
of 34
Critical Reviews in Oncology/Hematology
|
February 9, 2025
Unraveling the link between cholesterol and immune system in cancer: From biological mechanistic insights to clinical evidence. A narrative review
Federica Pecci, Valeria Cognigni, Giulia Claire Giudice, et al.
Immunotherapy
|
August 6, 2024
A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study
Shobana Anpalakhan, Giuseppe Luigi Banna, Sara Elena Rebuzzi, et al.
Future Oncology (London, England)
|
March 12, 2015
Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients
Orazio Caffo, Giovanni Lo Re, Teodoro Sava, et al.
Therapeutic Advances in Medical Oncology
|
March 3, 2022
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
Sara Elena Rebuzzi, Luigi Cerbone, Alessio Signori, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
July 11, 2024
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors
Giulia Mazzaschi, Fabiana Perrone, Giuseppe Maglietta, et al.
Journal of Kidney Cancer and VHL
|
October 20, 2025
Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI Study
Giulia Airò, Annalisa Guida, Alessio Gili, et al.
BJU International
|
February 28, 2012
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey
Cristina Masini, Roberto Sabbatini, Camillo Porta, et al.
Journal for Immunotherapy of Cancer
|
January 6, 2026
Dissecting the impact of Controlling Nutritional Status (CONUT) score on survival outcomes and immune-inflammatory profiles in patients with advanced NSCLC undergoing first-line immunotherapy
Federica Pecci, Giulia Mazzaschi, Alessandra Dodi, et al.
Critical Reviews in Oncology/Hematology
|
May 8, 2023
A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitoRS in solid tumors: The OTHERS study
Giorgio Bogani, Michela Cinquini, Diego Signorelli, et al.
Clinical Genitourinary Cancer
|
August 23, 2024
Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the Kidney
Giulia Claire Giudice, Marco Maruzzo, Elena Verzoni, et al.
Page
of 34